Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Nervous SystemDRG 062-ischemic-stroke-precerebral-occlusion-or-transient-ischemia-with-thrombolytic-agent-with-cc
    Ask Trek AI about this page

    Ischemic Stroke with Thrombolytic Agent and CC: Inpatient Reimbursement Overview

    DRG 062 covers ischemic stroke, precerebral occlusion, or transient ischemia cases where a thrombolytic agent was given and a Complication or Comorbidity is present; this classification reflects higher clinical complexity. Proper assignment of this Diagnosis-Related Group influences inpatient reimbursement by aligning payment with the additional resources associated with thrombolytic therapy and concurrent complications.

    Customize your policy alerts

    Sign up for drg 062 policy alerts

    Get alerted when payer policies referencing 062 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 062 Overview

    DRG 062 covers inpatient admissions for ischemic stroke, precerebral occlusion, or transient ischemia where a thrombolytic agent was administered and there is a Complication or Comorbidity. This Diagnosis-Related Group groups patients by the clinical event and the use of thrombolytic therapy, with added resource considerations when a Complication or Comorbidity is present. It matters for Medicare reimbursement because payment is adjusted based on the clinical complexity and therapies provided during the hospital stay. Accurate coding of the thrombolytic administration and the presence of Complications or Comorbidities affects the Diagnosis-Related Group assignment and payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute reperfusion strategy trials focusing on early administration and delivery methods of thrombolytic therapy in patients presenting with ischemic stroke or transient ischemic attack within the therapeutic time window. These studies enroll patients with confirmed precerebral or intracranial large-vessel occlusions who are eligible for systemic thrombolytics, and often compare time-to-treatment protocols, adjunctive imaging selection criteria, or novel administration techniques to optimize clot dissolution. Results inform in-hospital stroke pathways and resource allocation decisions for emergency departments and stroke units, impacting length of stay, complication rates, and short-term reimbursement drivers for this DRG.
    • Comparative effectiveness research evaluating adjunctive acute care interventions and complication prevention in thrombolysed stroke patients with complications or comorbid conditions (the CC population). Trials in this area test different blood pressure management strategies, glycemic control protocols, or prophylactic measures against hemorrhagic transformation and medical complications in patients with significant comorbid cardiovascular or metabolic disease. Findings are highly relevant to clinicians and payers because they can reduce complication-related utilization, readmissions, and cost variability within this DRG by identifying care bundles that improve safety without prolonging inpatient stays.
    • Post-discharge outcomes and care-transition studies examining early rehabilitation intensity, secondary prevention adherence, and coordinated outpatient follow-up for patients discharged after ischemic stroke who received thrombolytic therapy. These longitudinal studies follow heterogeneous survivors—many older with functional deficits and comorbidities—to assess interventions that reduce functional decline, recurrent vascular events, and rehospitalization over 30–365 days. For providers and payers, evidence from these studies guides discharge planning, outpatient service coverage, and investment in transitional care programs that can lower downstream costs and improve quality metrics associated with this DRG.

    Related Codes

    020-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITH-MCC

    Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with MCC: Inpatient Reimbursement Overview

    021-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITH-CC

    Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage with CC: Inpatient Reimbursement Overview

    022-INTRACRANIAL-VASCULAR-PROCEDURES-WITH-PRINCIPAL-DIAGNOSIS-HEMORRHAGE-WITHOUT-CC-MCC

    Intracranial Vascular Procedures with Principal Diagnosis Hemorrhage without CC/MCC: Inpatient Reimbursement Overview

    023-CRANIOTOMY-WITH-MAJOR-DEVICE-IMPLANT-OR-ACUTE-COMPLEX-CNS-PRINCIPAL-DIAGNOSIS-WITH-MCC-OR-ANTINEOPLASTIC-IMPLANT-OR-EPILEPSY-WITH-NEUROSTIMULATOR

    Craniotomy with Major Device Implant or Complex CNS DRG 023: Inpatient Reimbursement Overview

    024-CRANIOTOMY-WITH-MAJOR-DEVICE-IMPLANT-OR-ACUTE-COMPLEX-CNS-PRINCIPAL-DIAGNOSIS-WITHOUT-MCC

    Craniotomy with Major Device Implant or Acute Complex CNS Principal Diagnosis without MCC: Inpatient Reimbursement Overview

    025-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITH-MCC

    Craniotomy and Endovascular Intracranial Procedures with MCC: Inpatient Reimbursement Overview

    026-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITH-CC

    Craniotomy and Endovascular Intracranial Procedures with CC: Inpatient Reimbursement Overview

    027-CRANIOTOMY-AND-ENDOVASCULAR-INTRACRANIAL-PROCEDURES-WITHOUT-CC-MCC

    Craniotomy and Endovascular Intracranial Procedures without CC/MCC: Inpatient Reimbursement Overview

    028-SPINAL-PROCEDURES-WITH-MCC

    Spinal Procedures with MCC: Inpatient Reimbursement Overview

    029-SPINAL-PROCEDURES-WITH-CC-OR-SPINAL-NEUROSTIMULATORS

    Spinal Procedures with CC or Spinal Neurostimulators: Inpatient Reimbursement Overview

    Showing 1–10 of 71

    • More pages

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.